Aelix Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $13M
Latest Deal Amount
  • Investors
  • 3

Aelix Therapeutics General Information

Description

Owner and operator of a biotechnology company intended to develop a therapeutic vaccine to help people with HIV. The company's vaccine is based on a disruptive design of a T-cell immunogen that is able to elicit a strong broad and focused response against HIV and has the potential to radically transform the treatment of HIV infection, enabling patients to get cured from HIV diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Primary Office
  • Parc Científic de Barcelona
  • Carrer Baldiri i Reixac 4-8
  • 08028 Barcelona
  • Spain
+34 934 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aelix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 07-Aug-2020 $13M 0000 Completed Startup
To view Aelix Therapeutics’s complete valuation and funding history, request access »

Aelix Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Owner and operator of a biotechnology company intended to develop a therapeutic vaccine to help people with HIV. The com
Biotechnology
Barcelona, Spain
0000
00000000000 0000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
000000000000000
San Diego, CA
0 As of 0000
00.000
0000000000 0 00.000

0000000

modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
0000 000000000
Houston, TX
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aelix Therapeutics Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Viriom Venture Capital-Backed San Diego, CA 0 00.000 0000000000 0 00.000
0000000 Venture Capital-Backed Houston, TX 00 000.00 000000000 - 000.00
000000 Accelerator/Incubator Backed Fairway, KS 0 000.00 000000000000 000.00
0000000000 Corporate Backed or Acquired Australia 0 000.00 000000&0 000.00
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
You’re viewing 5 of 17 competitors. Get the full list »

Aelix Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
José Luis Cabero MD Chief Executive Officer
Christian Brander Ph.D Chief Scientific Officer & Co-Founder
Jordi Naval Co-Founder & Board Member
Bonaventura Clotet Ph.D Co-Founder, Observor & Member of Scientific Advisory Board
Lance Berman MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Aelix Therapeutics Board Members (8)

Name Representing Role Since
Bonaventura Clotet Ph.D Aelix Therapeutics Co-Founder, Observor & Member of Scientific Advisory Board 000 0000
Jeanne Bolger MD Johnson & Johnson Innovation - JJDC Board Member 000 0000
Jordi Naval Aelix Therapeutics Co-Founder & Board Member 000 0000
José Antonio Mesa CAIXA CAPITAL RISC Board Member 000 0000
Karen Wagner Ysios Capital Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Aelix Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CAIXA CAPITAL RISC Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Ysios Capital Venture Capital Minority 000 0000 000000 0
To view Aelix Therapeutics’s complete investors history, request access »